HomeAI · summaries
Storia in 2 fonti
Tolerability Concerns for GLP-1/Glucagon Agonist in Obesity, MASLD
Roughly one in five patients ditched survodutide due to adverse events
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
healio.com
Weekly survodutide confers dual benefits for obesity, metabolic liver disease
NEW ORLEANS — Once-weekly survodutide was linked with substantial reductions in body weight and liver fat content among individuals with obesity and metabolic…
- ·
medpagetoday.com
Monthly GLP-1 for Obesity Promising as More Manageable Alternative
Less frequent dosing could support better long-term adherence, says researcher
- ·
Tolerability Concerns for GLP-1/Glucagon Agonist in Obesity, MASLD
Roughly one in five patients ditched survodutide due to adverse events